The study was not set up to look at any differences between the two. That rose to more than 85% after the second dose. The numbers were very small and there was uncertainty over their significance, said the researchers. The Pfizer/BioNTech was available first so there is more data, but the Oxford/AstraZeneca was mostly used in the older age group. They needed further analyses with longer-term follow-up.
The study was not set up to look at any differences between the two.
( z0 set-up :ARG1 ( z1 study ) :ARG2 ( z2 look :ARG0 z1 :ARG1 ( z3 differ :ARG1 ( z4 thing :quant 2 ) :mod ( z5 any ) ) ) :polarity - )
(z0 / set-up-03
    :ARG1 (z1 / study)
    :ARG2 (z2 / look-01
              :ARG0 z1
              :ARG1 (z3 / differ-02
                        :ARG1 (z4 / thing
                                  :quant 2)
                        :mod (z5 / any)))
    :polarity -)
The study was not set up to look at any differences between the two .
z0 :polarity 0
z0 :ARG1 z1
z0 :ARG2 z2
z2 :ARG0 z1
z3 :mod z5
z2 :ARG1 z3
z3 :ARG1 z4
z4 :quant 1